Product Description
Mechanisms of Action: ADRA1A Agonist, ADRA1B Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Approved
Approved Countries: Bangladesh | India | Italy | Korea | Pakistan | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/20/2025 |
News Article |
Anti-Obesity Drug Market to Reach USD 82.55 Billion in 2032, Exclusive Report by Coherent Market Insights |
|
04/16/2025 |
News Article |
Best Appetite Suppressants - Natural Over the Counter (OTC) Appetite Suppressant for Hunger Control & Fat Burner ( Men & Women) - By Phenq CrazyBulk in USA |
